State Street Corp grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 1.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 12,024,456 shares of the pharmaceutical company's stock after purchasing an additional 152,997 shares during the quarter. State Street Corp owned about 4.74% of Vertex Pharmaceuticals worth $6,286,506,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently made changes to their positions in the business. MADDEN SECURITIES Corp bought a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Meeder Asset Management Inc. acquired a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at approximately $26,000. Community Financial Services Group LLC bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $26,000. Elevation Wealth Partners LLC increased its position in Vertex Pharmaceuticals by 103.7% in the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 28 shares during the period. Finally, Pingora Partners LLC bought a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $32,000. 90.96% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other news, Director Sangeeta Bhatia sold 271 shares of the firm's stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $547.86, for a total transaction of $148,470.06. Following the completion of the transaction, the director directly owned 4,653 shares of the company's stock, valued at approximately $2,549,192.58. This trade represents a 5.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Thornberry sold 1,000 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $547.86, for a total transaction of $547,860.00. Following the sale, the director owned 1,109 shares in the company, valued at approximately $607,576.74. This trade represents a 47.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 16,557 shares of company stock worth $9,071,071. Company insiders own 0.20% of the company's stock.
Vertex Pharmaceuticals Trading Down 1.1%
Shares of VRTX opened at $514.75 on Friday. Vertex Pharmaceuticals Incorporated has a 12-month low of $412.27 and a 12-month high of $568.67. The company has a quick ratio of 1.89, a current ratio of 2.34 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $130.51 billion, a price-to-earnings ratio of 33.12, a P/E/G ratio of 2.85 and a beta of 0.28. The stock's 50-day moving average price is $522.72 and its 200 day moving average price is $485.26.
Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.06). Vertex Pharmaceuticals had a net margin of 30.70% and a return on equity of 21.98%. The firm had revenue of $3.44 billion during the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the company earned $4.80 EPS. The company's revenue was up 11.8% on a year-over-year basis. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post 16.10 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research analysts have recently commented on VRTX shares. Wall Street Zen lowered Vertex Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, October 31st. Cantor Fitzgerald raised their price objective on shares of Vertex Pharmaceuticals from $595.00 to $619.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 3rd. TD Cowen boosted their target price on shares of Vertex Pharmaceuticals from $550.00 to $575.00 and gave the stock a "buy" rating in a research report on Tuesday, November 3rd. Stifel Nicolaus upped their target price on shares of Vertex Pharmaceuticals from $500.00 to $563.00 and gave the company a "hold" rating in a research note on Tuesday, November 3rd. Finally, Royal Bank Of Canada upped their target price on shares of Vertex Pharmaceuticals from $576.00 to $600.00 and gave the company an "outperform" rating in a research note on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $596.44.
Check Out Our Latest Report on Vertex Pharmaceuticals
About Vertex Pharmaceuticals
(
Free Report)
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex's CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
See Also
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Vertex Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.
While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.